News Sentiment

RGNX sentiment intelligence

Regenxbio Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 45 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 9.89 Week of 17 Jul 2026
Weighted tone 45/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

-29.1% over one week, +26.8% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

REGENXBIO Inc. (RGNX) stock price, news, quote and history

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -29.1% Price reacting lower
Trend fit Trend inactive 26.8% over four weeks
Fair value -17.8% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 32
Negative 19

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
Stock Titan 9
Investing.com 5
simplywall.st 5
PR Newswire 3
MT Newswires 3
Reuters 3
AllSci 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 10
Regulatory and legal 8
Balance sheet 5
Guidance 2
Deals and strategy 2
Analyst action 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 60
Eyes On Eyecare Direct company coverage

RegenxBio doses first patient in phase 2b/3 trial for DR

RegenxBio has dosed the first patient in its phase 2b/3 NAAVIGATE trial for surabgene lomparvovec (sura-vec, ABBV-RGX-314) for diabetic retinopathy (DR) using suprachoroidal delivery. This gene therapy, developed in partnership with AbbVie, utilizes RegenxBio's proprietary NAV Te

Tone
Neutral 50/100
Event
Deals and strategy
Published
10 Jul 2026 17:40
Source
Eyes On Eyecare
Stock Traders Daily Direct company coverage

(RGNX) Movement as an Input in Quant Signal Sets

This article from Stock Traders Daily analyzes Regenxbio Inc. (NASDAQ: RGNX) using AI models, identifying strong near and mid-term sentiment but a weak long-term outlook. It provides specific institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with entry

Tone
Positive 67/100
Event
Guidance
Published
09 Jul 2026 16:10
Source
Stock Traders Daily
AD HOC NEWS Direct company coverage

Regenxbio Inc outlines gene therapy pipeline as Nasdaq-listed biotech stays focused on long-term gro

Regenxbio Inc. is a Nasdaq-listed gene therapy company focusing on long-term growth through its clinical pipeline and licensing model in rare diseases and ophthalmology. The company utilizes proprietary AAV vector technology to develop gene therapies designed for durable treatmen

Tone
Positive 82/100
Event
Market update
Published
07 Jul 2026 16:42
Source
AD HOC NEWS